SA109300673B1 - 1-(أريل سلفونيل)-4-(بيبرازين-1- يل)-1h- بنزيميدازولات كمركبات ترابطية 5- هيدروكسي تريبتامين-6 - Google Patents

1-(أريل سلفونيل)-4-(بيبرازين-1- يل)-1h- بنزيميدازولات كمركبات ترابطية 5- هيدروكسي تريبتامين-6 Download PDF

Info

Publication number
SA109300673B1
SA109300673B1 SA109300673A SA109300673A SA109300673B1 SA 109300673 B1 SA109300673 B1 SA 109300673B1 SA 109300673 A SA109300673 A SA 109300673A SA 109300673 A SA109300673 A SA 109300673A SA 109300673 B1 SA109300673 B1 SA 109300673B1
Authority
SA
Saudi Arabia
Prior art keywords
benzimidazole
sulfonyl
piperazin
compound
methyl
Prior art date
Application number
SA109300673A
Other languages
Arabic (ar)
English (en)
Inventor
Simon Nicolas Haydar
Patrick Michael Andrae
Heedong Yun
Albert Jean Robichaud
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA109300673(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SA109300673B1 publication Critical patent/SA109300673B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SA109300673A 2008-11-11 2009-11-11 1-(أريل سلفونيل)-4-(بيبرازين-1- يل)-1h- بنزيميدازولات كمركبات ترابطية 5- هيدروكسي تريبتامين-6 SA109300673B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
SA109300673B1 true SA109300673B1 (ar) 2013-05-25

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
SA109300673A SA109300673B1 (ar) 2008-11-11 2009-11-11 1-(أريل سلفونيل)-4-(بيبرازين-1- يل)-1h- بنزيميدازولات كمركبات ترابطية 5- هيدروكسي تريبتامين-6

Country Status (41)

Country Link
US (1) US8063053B2 (cg-RX-API-DMAC7.html)
EP (1) EP2285784B1 (cg-RX-API-DMAC7.html)
JP (1) JP5087171B2 (cg-RX-API-DMAC7.html)
KR (1) KR101323417B1 (cg-RX-API-DMAC7.html)
CN (1) CN102209713B (cg-RX-API-DMAC7.html)
AP (1) AP2814A (cg-RX-API-DMAC7.html)
AR (1) AR074325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314221B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0920682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2740262C (cg-RX-API-DMAC7.html)
CL (1) CL2011001050A1 (cg-RX-API-DMAC7.html)
CO (1) CO6440548A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110247A (cg-RX-API-DMAC7.html)
CU (1) CU24020B1 (cg-RX-API-DMAC7.html)
CY (1) CY1113025T1 (cg-RX-API-DMAC7.html)
DK (1) DK2285784T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000130A (cg-RX-API-DMAC7.html)
EA (1) EA018369B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011045A (cg-RX-API-DMAC7.html)
ES (1) ES2389694T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20135805B (cg-RX-API-DMAC7.html)
HR (1) HRP20120561T1 (cg-RX-API-DMAC7.html)
IL (1) IL212213A0 (cg-RX-API-DMAC7.html)
MA (1) MA32788B1 (cg-RX-API-DMAC7.html)
ME (1) ME01129B (cg-RX-API-DMAC7.html)
MX (1) MX2011004996A (cg-RX-API-DMAC7.html)
MY (1) MY156324A (cg-RX-API-DMAC7.html)
NI (1) NI201100093A (cg-RX-API-DMAC7.html)
NZ (1) NZ592563A (cg-RX-API-DMAC7.html)
PE (1) PE20120026A1 (cg-RX-API-DMAC7.html)
PL (1) PL2285784T3 (cg-RX-API-DMAC7.html)
PT (1) PT2285784E (cg-RX-API-DMAC7.html)
RS (1) RS52381B (cg-RX-API-DMAC7.html)
SA (1) SA109300673B1 (cg-RX-API-DMAC7.html)
SI (1) SI2285784T1 (cg-RX-API-DMAC7.html)
SV (1) SV2011003902A (cg-RX-API-DMAC7.html)
TN (1) TN2011000203A1 (cg-RX-API-DMAC7.html)
TW (1) TWI481605B (cg-RX-API-DMAC7.html)
UA (1) UA100192C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010056644A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103283B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0515482A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
JP5080256B2 (ja) * 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−CoAデサチュラーゼ(SCD)のインヒビターとしてのそれらの使用
MX2007003332A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US12398097B2 (en) 2019-07-29 2025-08-26 Vanderbilt University WDR5-MYC inhibitors
CN117242055A (zh) * 2020-04-22 2023-12-15 里科瑞尔姆Ip控股有限责任公司 选择性雌激素受体降解剂的制备

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003400A1 (en) 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1087294C (zh) 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DK0930302T3 (da) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
KR100472126B1 (ko) 1998-08-10 2005-03-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 양성자 펌프 억제제의 프로드러그
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
MXPA03011638A (es) * 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
EP1556140A4 (en) 2002-10-15 2006-04-19 Synta Pharmaceuticals Corp NEW COMPOUNDS
CA2563895C (en) 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006015259A2 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
DOP2011000130A (es) 2017-04-30
AU2009314221B2 (en) 2012-08-30
NI201100093A (es) 2011-10-31
ES2389694T3 (es) 2012-10-30
CU20110101A7 (es) 2012-01-31
EA018369B1 (ru) 2013-07-30
JP2012508275A (ja) 2012-04-05
EP2285784A1 (en) 2011-02-23
CA2740262A1 (en) 2010-05-20
CN102209713A (zh) 2011-10-05
CO6440548A2 (es) 2012-05-15
MX2011004996A (es) 2011-05-25
BRPI0920682A2 (pt) 2016-09-27
AP2814A (en) 2013-12-31
ME01129B (me) 2013-03-20
DK2285784T3 (da) 2012-07-23
US8063053B2 (en) 2011-11-22
SV2011003902A (es) 2011-07-05
MY156324A (en) 2016-02-15
NZ592563A (en) 2012-10-26
PT2285784E (pt) 2012-09-19
AU2009314221A1 (en) 2010-05-20
CY1113025T1 (el) 2016-04-13
IL212213A0 (en) 2011-06-30
EA201100696A1 (ru) 2011-10-31
CR20110247A (es) 2011-06-24
CU24020B1 (es) 2014-07-30
GEP20135805B (en) 2013-04-10
TN2011000203A1 (fr) 2012-12-17
TWI481605B (zh) 2015-04-21
US20100120779A1 (en) 2010-05-13
WO2010056644A8 (en) 2010-11-18
ECSP11011045A (es) 2011-06-30
RS52381B (sr) 2012-12-31
HK1158647A1 (en) 2012-07-20
UA100192C2 (en) 2012-11-26
KR20110075013A (ko) 2011-07-05
CL2011001050A1 (es) 2011-08-19
HRP20120561T1 (hr) 2012-07-31
MA32788B1 (fr) 2011-11-01
KR101323417B1 (ko) 2013-10-29
JP5087171B2 (ja) 2012-11-28
PL2285784T3 (pl) 2012-12-31
AR074325A1 (es) 2011-01-05
TW201022247A (en) 2010-06-16
AP2011005664A0 (en) 2011-04-30
PE20120026A1 (es) 2012-02-12
EP2285784B1 (en) 2012-07-04
CA2740262C (en) 2013-05-28
ZA201103283B (en) 2012-01-25
SI2285784T1 (sl) 2012-08-31
WO2010056644A1 (en) 2010-05-20
CN102209713B (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
SA109300673B1 (ar) 1-(أريل سلفونيل)-4-(بيبرازين-1- يل)-1h- بنزيميدازولات كمركبات ترابطية 5- هيدروكسي تريبتامين-6
TW593278B (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6727246B2 (en) 1-(aminoalkyl)-3-sulfonylindole-and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP2006517966A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルアザインドールまたは−アザインダゾール誘導体
US20070281922A1 (en) 1-Sulfonylindazolylamine and - amide derivatives as 5-hydroxytryptamine-6 ligands
CA2844704A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
JP3157179B2 (ja) 3−アリールカルボニル−1−アミノアルキル−1h−インドール含有抗緑内障組成物
KR20050101551A (ko) 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
CZ20022880A3 (cs) Deriváty chinolinu jako alfa 2 antagonisté
MXPA06005103A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de 5-hidroxitriptamina-6.
HRP940960A2 (en) N-substituted azabicycloheptane derivatives, the preparation and use thereof
CA3031006A1 (en) Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof
JP2009533441A (ja) 5‐ヒドロキシトリプタミン‐6リガンドとしての置換ジヒドロ[1,4]オキサジノ[2,3,4‐hi]インダゾール誘導体
US7534801B2 (en) Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
US20070099912A1 (en) Pyrrolo[2,3-F] and [3,2-F]Isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
JP2009532471A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニル−3−ヘテロシクリルインダゾール誘導体
HK1158647B (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands